Form 4: Astria Therapeutics Director Cashes In Options Post-Merger

Astria Therapeutics director Kenneth Bate received cash for in-the-money stock options following the company's merger with BioCryst Pharmaceuticals, Inc.

Summary

• Astria Therapeutics, Inc. merged with Axel Merger Sub, Inc., a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc., on January 23, 2026.
• Following the merger, Astria Therapeutics became a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc.
• Kenneth Bate, a director of Astria Therapeutics, reported changes in his beneficial ownership of derivative securities (stock options) due to the merger.
• In-the-money stock options (exercise price less than $13.00) held by Kenneth Bate became fully vested and were canceled in exchange for cash.
• The cash payment for in-the-money options was calculated as the product of the number of shares subject to the option and the excess of $13.00 over the option's exercise price.
• Out-of-the-money stock options (exercise price equal to or greater than $13.00) were canceled for no consideration and are not reported.
• The reported stock option numbers reflect a 1-for-6 reverse stock split effected by Astria Therapeutics on August 19, 2021.

Sentiment

Score: 7

Explanation: The sentiment is positive for the reporting person as they successfully monetized their in-the-money options. For the company, it marks the completion of an acquisition, ending its independent public status, which can be viewed as a successful exit for shareholders but also a loss of autonomy.

Positives

• Kenneth Bate received cash payments for his in-the-money stock options, totaling approximately $364,488.66.
• The merger provided a liquidity event for holders of in-the-money options and shareholders of Astria Therapeutics.

Negatives

• Out-of-the-money stock options held by Kenneth Bate were canceled for no consideration.
• Astria Therapeutics ceased to be an independent publicly traded company, becoming a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc.

Future Outlook

This filing reports a completed transaction and does not provide forward-looking statements or guidance regarding the future operations or financial performance of the combined entity.

Industry Context

The merger represents a consolidation event within the biotechnology and pharmaceutical industry, where smaller companies like Astria Therapeutics are acquired by larger players such as BioCryst Pharmaceuticals, Inc. This is a common strategy for expanding product pipelines or market reach.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders of Astria Therapeutics would have received consideration (cash or BioCryst shares, as per the merger agreement not detailed here) for their shares, ending their investment in an independent entity.
• Holders of in-the-money stock options received cash payments, while holders of out-of-the-money options received no consideration.
• Employees of Astria Therapeutics are now part of the larger BioCryst organization, potentially impacting roles, benefits, and corporate culture.

Next Steps

• Astria Therapeutics will operate as a wholly-owned subsidiary of BioCryst Pharmaceuticals, Inc.

Key Dates

Keywords

Astria Therapeutics, ATXS, BioCryst Pharmaceuticals, Merger, Stock Options, Insider Transaction, Form 4, Corporate Governance, Acquisition